Defining curative endpoints for sickle cell disease in the era of gene therapy and gene editing

Abstract excerpt

A growing number of gene therapy- and gene editing-based treatments for patients with sickle cell disease (SCD) are entering clinical trials. These treatments, designed to target the underlying cause of SCD, have the potential to provide functional cures, which until now were possible only through allogeneic hematopoietic stem cell transplant. However, as these novel approaches advance from early- to late-stage...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Hemoglobinopathies and Related Disorders
• Share to Iron Metabolism and Disorders
• Share to Prenatal Screening and Diagnostics